Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines

Galderma

Status and phase: Completed; Phase 3

Conditions: Glabellar Frown Lines; Canthal Lines

Treatments: Biological: QM1114-DP

Study type: Interventional

Funder types: Industry

Identifiers

NCT05148000

43QM2107

Details and patient eligibility

About

This study to assess aesthetic improvement following treatment with QM1114-DP.

Full description

This is an open-label, single-center multi-center study to assess aesthetic improvement in the Glabellar and Lateral Canthal regions following treatment with QM1114-DP.

Enrollment: 25 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Male or Female 18 years or older
• Moderate to severe bilaterally symmetrical LCL as assessed by the investigator
• Moderate to severe GL at maximum frown as assessed by the Investigator

Exclusion criteria

• Previous use of any botulinum toxin in facial areas within 9 months prior to study treatment
• Female who is pregnant, breast feeding or intends to conceive a child during the study.
• Known allergy to hypersensitivity or any component of the Investigational product

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

25 participants in 1 patient group

QM1114-DP

Experimental group

Description:

QM1114-DP

Treatment:

Biological: QM1114-DP